Envestnet Portfolio Solutions Inc. Decreases Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Envestnet Portfolio Solutions Inc. trimmed its holdings in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 10.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 33,828 shares of the medical research company's stock after selling 3,811 shares during the quarter. Envestnet Portfolio Solutions Inc.'s holdings in Edwards Lifesciences were worth $2,504,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Empowered Funds LLC boosted its stake in Edwards Lifesciences by 10.7% in the third quarter. Empowered Funds LLC now owns 24,032 shares of the medical research company's stock valued at $1,586,000 after acquiring an additional 2,324 shares during the last quarter. Quest Partners LLC acquired a new position in shares of Edwards Lifesciences in the 3rd quarter valued at $406,000. Avior Wealth Management LLC boosted its position in shares of Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company's stock worth $35,000 after purchasing an additional 308 shares during the last quarter. Prospera Private Wealth LLC acquired a new stake in shares of Edwards Lifesciences during the third quarter worth $32,000. Finally, Connor Clark & Lunn Investment Management Ltd. increased its holdings in Edwards Lifesciences by 32.1% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 213,700 shares of the medical research company's stock valued at $14,102,000 after purchasing an additional 51,896 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

Remove Ads

Edwards Lifesciences Stock Performance

Shares of NYSE EW traded down $0.06 during trading on Tuesday, hitting $71.29. The company had a trading volume of 6,112,449 shares, compared to its average volume of 4,612,307. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The firm has a market capitalization of $41.91 billion, a P/E ratio of 10.23, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The stock has a 50 day simple moving average of $71.43 and a 200 day simple moving average of $70.42.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 9,500 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $67.96, for a total value of $645,620.00. Following the completion of the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,189,770.56. The trade was a 16.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the sale, the vice president now directly owns 23,189 shares of the company's stock, valued at approximately $1,594,475.64. This trade represents a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 51,303 shares of company stock worth $3,715,776 over the last 90 days. 1.29% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on EW shares. Truist Financial restated a "hold" rating and set a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Canaccord Genuity Group boosted their price objective on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the company a "hold" rating in a report on Thursday, February 13th. Morgan Stanley increased their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a report on Wednesday, February 12th. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and upped their price objective for the company from $75.00 to $90.00 in a research report on Thursday, January 30th. Finally, Piper Sandler boosted their target price on Edwards Lifesciences from $70.00 to $73.00 and gave the company a "neutral" rating in a research note on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.